1. When focusing on Medicaid fraud scenarios involving prescribed managed substances or when the Attorney Common has initiated an evaluation of distinct identifiers of Medicaid fraud or precise identifiers that warrant a Medicaid investigation regarding prescribed controlled substances. one(b) To protect personally identifiable information a